Results 171 to 180 of about 13,099 (221)

Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. [PDF]

Cancer Rep (Hoboken)
Mohammadkarimi V, Khalafi-Nezhad A, Najafi B, Alemzadeh N, Ghanbarinasab Z, Vahid R.   +5 more
europepmc   +1 more source

BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ. [PDF]

MedComm (2020)
Lu X, Fang H, Liu Y, Liu C, Fang X, Matsunaga A, Mori SF, Zhang T, Wang G, Zhou GI, Yu M, Ding H, Cortes J, Cheng B, Hu T.   +14 more
europepmc   +1 more source

Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs. [PDF]

Front Pharmacol
Massimino M, Tirrò E, Romano C, Stella S, Tomarchio C, Vitale SR, Manzella L, Di Raimondo F, Stagno F, Vigneri P.   +9 more
europepmc   +1 more source

Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities. [PDF]

Cancers (Basel)
Caprino F, Valentino I, Bruzzese A, Ganino L, Mesuraca M, Citraro R, Gentile M, Gallo Cantafio ME, Amodio N.   +8 more
europepmc   +1 more source

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib. [PDF]

Pharmaceuticals (Basel)
Hajjo R, Sabbah DA, Alhaded R, Alquabe'h A, Bardaweel SK.   +4 more
europepmc   +1 more source

Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib. [PDF]

Ann Hematol
Yu L, Jiang Q.
europepmc   +1 more source

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. [PDF]

Hematol Transfus Cell Ther
Avinery L, Regev D, Khamaisi H, Gopas J, Mahajna J.   +4 more
europepmc   +1 more source